Breaking News, Collaborations & Alliances

Tubulis, Bristol Myers Squibb Join Forces to Develop Next-Gen ADCs for Cancer

BMS to obtain access to Tubulis’ P5 conjugation and Tubutecan platforms to develop customizable antibody-drug conjugates for cancer.

Tubulis and Bristol Myers Squibb entered into a strategic license agreement to develop differentiated antibody-drug conjugates (ADCs). Through the agreement, BMS will gain exclusive rights to access Tubulis’ Tubutecan payloads in combination with Tubulis’ proprietary P5 conjugation platform for the development of a selected number of highly differentiated ADCs to treat solid tumors. P5 and Tubutecans facilitate the generation of ultra-stable ADCs that have the potential to actively reduce unw...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters